Cargando…
A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy
Breast cancer is the most common cancer in women worldwide. A new promising anti-cancer therapy involves the use of monoclonal antibodies specific for target tumor-associated antigens (TAAs). A TAA of interest for immunotherapy of Triple Negative Breast Cancer (TNBC) is nucleolin (NCL), a multifunct...
Autores principales: | D'Avino, Chiara, Palmieri, Dario, Braddom, Ashley, Zanesi, Nicola, James, Cindy, Cole, Sara, Salvatore, Francesco, Croce, Carlo M., De Lorenzo, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349967/ https://www.ncbi.nlm.nih.gov/pubmed/27894092 http://dx.doi.org/10.18632/oncotarget.13522 |
Ejemplares similares
-
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours
por: Borriello, M, et al.
Publicado: (2011) -
Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells
por: Jordaan, Sandra, et al.
Publicado: (2018) -
NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs
por: Sheetz, Tyler, et al.
Publicado: (2020) -
Photoelectron Photoion Coincidence Spectroscopy of NCl(3) and NCl(2)
por: Gerlach, Marius, et al.
Publicado: (2021) -
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
por: Pichiorri, Flavia, et al.
Publicado: (2013)